GlassScriptPhysician profile
James Thomas Broome
NPI 1366599235
$3,119.59
in general payments reported to CMS, 2019-2025
9 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.44 · 2022: $147 · 2023: $317 · 2024: $2,534 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,205 · Food and Beverage: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,205.00 |
| Food and Beverage | $750.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $2,418.24 | 2020-2024 | Korlym |
| Amgen INC. | $258.92 | 2023-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $165.25 | 2022-2024 | Rybelsus, Ozempic, Tresiba |
| Renalytix Ai, INC. | $98.69 | 2022 | |
| Olympus America INC. | $73.03 | 2023-2025 | Olympus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.06 | 2022-2023 | Jardiance, Synjardy |
| Amryt Pharma Holdings LTD | $26.61 | 2023 | Mycapssa |
| Amneal Pharmaceuticals LLC | $19.16 | 2024 | Unithroid |
| Abbvie INC. | $15.63 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Broome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.